Urine metabolomics for kidney cancer detection and biomarker discovery

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 5, 2011, Pages 551-557

  Ganti, Sheila ^a,b   Weiss, Robert H ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Biomarker; Kidney; Metabolomics; Renal cell carcinoma; Urine

Indexed keywords

2 OXOGLUTARIC ACID; BIOLOGICAL MARKER; QUINOLINIC ACID; TUMOR MARKER; UREA;

BIOMARKER DISCOVERY; CANCER DIAGNOSIS; DATA ANALYSIS; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EXPERIMENT; GAS CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; KIDNEY CONCENTRATING CAPACITY; LIQUID CHROMATOGRAPHY; METABOLISM; METABOLITE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROCESSING; REVIEW; STANDARDIZATION; URINALYSIS; URINE; VALIDATION STUDY;

HUMANS; KIDNEY NEOPLASMS; METABOLOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052945596     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.05.013     Document Type: Review

References (16)

1. Griffiths W.J., Koal T., Wang Y., et al. Targeted metabolomics for biomarker discovery. Angew Chem Int Ed 2010, 49:5426-5445.
2. German J.B., Hammock B.D., Watkins S.M. Metabolomics: Building on a century of biochemistry to guide human health. Metabolomics 2005, 1:3-9.
3. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
4. Cella D., Cappelleri J.C., Bushmakin A., et al. Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib vs. interferon α. J Oncology Prac 2009, 5:66-70.
5. Kim K., Aronov P., Zakharkin S.O., et al. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteom 2009, 8:558-570.
6. Ryana D., Robards K., Prenzler P.D., et al. Recent and potential developments in the analysis of urine: A review. Anal Chim Acta 2011, 684:17-29.
7. Kind T., Tolstikov V., Fiehn O., et al. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem 2007, 363:185-195.
8. Saude E.J., Sykes B.D. Urine stability for metabolomic studies: Effects of preparation and storage. Metabolomics 2007, 3:19-27.
9. Schripsema J. Application of NMR in plant metabolomics: Techniques, problems, and prospects. Phytochem Anal 2009, 21:14-21.
10. Zuppi C., Messana I., Forni F., et al. 1H NMR spectra of normal urines reference ranges of the major metabolites. Clin Chim Acta 1997, 265:85-97.
11. Taylor S.L., Ganti S., Bukanov N.O., et al. A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am J Physiol Renal Physiol 2010, 298:F909-F922.
12. Kim K., Taylor S.L., Ganti S., et al. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS 2011, 15:293-303.
13. Kim K.B., Yang J.Y., Kwack S.J., et al. Toxicometabolomics of urinary biomarkers for human gastric cancer in a mouse model. J Toxicol Environ Health A 2010, 73:1420-1430.
14. Schaefer M.L., Wongravee K., Holmboe M.E., et al. Mouse urinary biomarkers provide signatures of maturation, diet, stress level, and diurnal rhythm. Chem Senses 2010, 35:459-471.
15. Perroud B., Ishimaru T., Borowsky A.D., et al. Grade-dependent proteomics characterization of kidney cancer. Mol Cell Proteom 2009, 8:971-985.
16. Sun C.Y., Zang Y.C., San Y.X., et al. Proteomic analysis of clear cell renal cell carcinoma. Saudi Med J 2010, 31:525-532.